Modular biologics platform designed to selectively engage and modulate disease-specific T cells for autoimmune, inflammatory, and oncology indications. Enables selective Treg induction/expansion, targeted cell depletion via anti-viral T cell redirection, and tumor-specific T cell activation.

Targets: TGF-β, IL-2, T cells, Tregs

Biotech Distilled coverage (3)

2026-07-10 UPDATE: Cue Biopharma (CUE) - The $50M Vote of Confidence and the CSU Clock
2026-06-02 UPDATE: Cue Biopharma (CUE) - The Horizon Crew Takes the Board
2026-05-20 Cue Biopharma, Inc. (CUE) — Scientific Deep Dive for CUE-221 and Pipeline Products 🔒 Paid

Articles open on Substack. Some deep dives are subscriber-only.